Algorae Pharmaceuticals advances cancer research with second validation program. The ASX-listed biotech company has partnered with Peter MacCallum Cancer Centre's Victorian Centre for Functional Genomics to independently validate its AlgoraeOS version 2 platform. The program will evaluate 24 high-priority drug combinations across four cancer types including glioblastoma, melanoma, and leukaemia. Algorae's proprietary platform has demonstrated superior performance compared to leading models from Google DeepMind, analyzing over 500,000 potential drug-cell line combinations. Preclinical data is expected within six months, potentially de-risking further development and accelerating the path toward clinical applications in oncology.
